National clinical trials offered at Massey utilize precision medicine aimed at improving treatment of early-stage lung cancer
VCU Massey Cancer Center is currently offering clinical trials for patients with early-stage lung cancer that utilize cutting-edge precision medicine techniques with the aim of improving treatment. This group of three integrated national clinical trials known as ALCHEMIST – Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials – use next-generation sequencing to identify patients with early-stage lung cancer whose tumors harbor specific and uncommon changes in two particular genes, epidermal growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK), thought to drive cancer growth.
Chat on the emotional side of healing
The Emotional Side of Healing was the subject of ABC News National Health’s weekly Twitter chat this past week, and patients, caregivers and clinicians were all asked to weigh-in on this area of interest. VCU Massey Cancer Center’s Egidio Del Fabbro, M.D., program director of palliative care, and Danielle Noreika, M.D., medical director of inpatient palliative care services, provided expert commentary as the moderator posed a series of questions and discussion topics.
Massey research leads to multi-institutional phase 1 clinical trial for relapsed/refractory aggressive lymphomas
Virginia Commonwealth University Massey Cancer Center researcher Steven Grant, M.D., is the co-principal investigator (PI) on a National Comprehensive Cancer Network (NCCN) grant funding a phase 1 clinical trial testing the drugs volasertib and belinostat in patients with relapsed and refractory aggressive B-cell and T-cell lymphomas. The $453,852 award will help implement the clinical trial at Massey, Yale Comprehensive Cancer Center and Johns Hopkins’ Sidney Kimmel Comprehensive Cancer Center.
Massey investigator selected for the Lymphoma Research Foundation’s Clinical Research Mentoring Program
The Lymphoma Research Foundation (LRF) has accepted VCU Massey Cancer Center researcher Victor Yazbeck, M.D., into its Clinical Research Mentoring Program (CRMP). The CRMP is a two-year program that selects up-and-coming lymphoma researchers to participate in educational courses, laboratory work and clinical studies in order to further their own research goals.
Massey scientists contribute to research involving the latest FDA-approved cancer therapies
VCU Massey Cancer Center doctors and scientists are making important discoveries involving cancer-fighting drugs recently approved by the U.S. Food and Drug Administration (FDA). Between August 2013 and July 2014, the FDA approved six new anticancer therapeutics, five of which target the unique molecular and genetic characteristics of an individual’s cancer.